Title : Repurposing of Clinically Approved Poly-(ADP-Ribose) Polymerase Inhibitors for the Therapy of Sepsis.

Pub. Date : 2021 Dec 1

PMID : 34115723

1 Functional Relationships(s)
Compound Name
Protein Name
1 The benefit of olaparib and other clinically approved PARP inhibitors has already been demonstrated in several experimental models of human diseases, such as neurodegeneration and neuroinflammation, acute hepatitis, skeletal muscle disorders, aging and acute ischemic stroke, protecting, for example, from the deterioration of the blood-brain barrier, restoring the cellular levels of NAD+, improving mitochondrial function and biogenesis and, among other effects, reducing oxidative stress and pro-inflammatory mediators, such as TNF-alpha, IL1-beta, IL-6 and VCAM1. NAD poly(ADP-ribose) polymerase 1 Homo sapiens